Breaking News

Biotest, ADMA Bio in Long-Term Supply Pact

January 11, 2013

Biotest to provide RSV Immune Globulin

Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG, has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics, Inc. (ADMA).
ADMA has agreed to purchase its worldwide requirements of RSV (Respiratory Syncytial Virus) Immune Globulin manufactured from human plasma, exclusively from BPC. The initial term of the agreement is for ten years. BPC will receive payment for manufacturing services as well as specified royalties on ADMA's product sales. In exchange, BPC granted ADMA a license to use its fractionation and purification manufacturing process for Intravenous Immune Globulin.
"We are very pleased to partner with ADMA on their lead product candidate.  Our ability to provide specialized contract manufacturing services will enable us to diversify our future revenue sources," said Jordan Siegel, chief executive officer of BPC.

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks